公开(公告)号：US20240252488A1

公开(公告)日：2024-08-01

申请号：US18246773

申请日：2021-09-27

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  HUONS CO., LTD.

Inventor： Jong Yeon HWANG ,  Hyunjun KIM ,  Hyowon MUN ,  Hyun Jin KIM ,  Jae Du HA ,  Sung Yun CHO ,  Chang Soo YUN ,  Pilho KIM ,  Jisoo LEE ,  Joon Gyo OH

IPC: A61K31/497 ,  A61K31/4439 ,  A61K31/444 ,  A61K47/54 ,  A61K47/55 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

CPC classification number: A61K31/497 ,  A61K31/4439 ,  A61K31/444 ,  A61K47/545 ,  A61K47/55 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: The present disclosure provides a compound of a specific chemical structure binding to MLKL or having an MLKL inhibiting or degrading activity, or pharmaceutically acceptable salts thereof. The present disclosure provides a composition comprising such compound or pharmaceutically acceptable salts thereof. The present disclosure provides the pharmaceutical use of the compound according to the present invention, salts thereof, and a composition comprising same for treating or preventing MLKL-related diseases. The present disclosure also provides a method for treating or preventing MLKL-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present invention, salts thereof, or a composition comprising same.

公开(公告)号：US20240018123A1

公开(公告)日：2024-01-18

申请号：US18017997

申请日：2021-07-28

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  UBIX THERAPEUTICS, INC.

Inventor： Jong Yeon HWANG ,  Jae Du HA ,  Hyun Jin KIM ,  Sung Yun CHO ,  Pilho KIM ,  Chong Ock LEE ,  Jeong Hoon KIM ,  Byoung Chul PARK ,  Sung Goo PARK ,  Sunhong KIM ,  Yuri CHOI ,  Yaejin WOO ,  Song Hee LEE ,  Je Ho RYU ,  Jungmin AHN ,  Ji Youn PARK ,  Onnuri BAE ,  Hanwool KIM

IPC: C07D401/14 ,  C07D295/155 ,  C07D211/26

CPC classification number: C07D401/14 ,  C07D211/26 ,  C07D295/155

Abstract: The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.

公开(公告)号：US20170145007A1

公开(公告)日：2017-05-25

申请号：US15319151

申请日：2015-05-21

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Chang Soo YUN ,  Hyoung Rae KIM ,  Sung Yun CHO ,  Hee Jung JUNG ,  Kwangho LEE ,  Chong Hak CHAE ,  Chong Ock LEE ,  Chi Hoon PARK ,  Pilho KIM ,  Jong Yeon HWANG ,  Jae DU HA ,  Sun Joo AHN

IPC: C07D471/04 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  C07D401/12

CPC classification number: C07D471/04 ,  A61K31/506 ,  C07D209/04 ,  C07D239/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14

Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.

公开(公告)号：US20220105188A1

公开(公告)日：2022-04-07

申请号：US17429321

申请日：2020-02-07

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Jong Yeon HWANG ,  Jae Du HA ,  Sung Yun CHO ,  Pilho KIM ,  Chang Soo YUN ,  Hyun Jin KIM ,  Sung Goo PARK ,  Byoung Chul PARK ,  Jeong Hoon KIM ,  Sunhong KIM

IPC: A61K47/55 ,  A61K47/54

Abstract: The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., EED or PRC2, utilizing cereblon E3 ubiquitin ligase, VHL E3 ubiquitin ligase, MDM2 E3 ubiquitin ligase, and cIAP E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

公开(公告)号：US20180104242A1

公开(公告)日：2018-04-19

申请号：US15567224

申请日：2015-12-30

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Yeon HWANG ,  Hyoung Rae KIM ,  Jae Du HA ,  Sung Yun CHO ,  Hee Jung JUNG ,  Pilho KIM ,  Chang Soo YUN ,  Chong Ock LEE ,  Chi Hoon PARK ,  Chong Hak CHAE ,  Sunjoo AHN

IPC: A61K31/506 ,  A61P35/00 ,  C07D239/48 ,  C07D239/30 ,  C07C13/48 ,  C07B43/04

CPC classification number: A61K31/506 ,  A23L33/10 ,  A61P35/00 ,  C07B43/04 ,  C07B2200/07 ,  C07C13/48 ,  C07D239/30 ,  C07D239/48

Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.